Retinitis Pigmentosa Clinical Trial
Official title:
Stress and Vision Fluctuations in Retinitis Pigmentosa
Verified date | August 2008 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Retinitis pigmentosa (RP) patients experience a slowly progressive, unpredictable loss of vision which eventually leads to bare or no light perception, posing a continuous threat to patients' independence. Negative psychological states such as distress, sleepiness, anxiety and depression are common in RP patients due to the nature of this chronic, disabling disease. Psychophysical vision measures are more variable in legally blind RP subjects than in normally sighted individuals, and RP patients indicate that variations in vision are often related to stress. The primary goal of this research is to examine the vision fluctuations within and between days among RP patients using vision tests self-administered by patients through their home computers, and determine associations with factors such as perceived stress, mood states, sleepiness, or light exposure. The administration of questionnaires will allow us to gain some insight into which underlying psychological factors impact certain vision measures, allowing the design of future interventional research to attempt to reduce such factors. The aims of many future treatment clinical trials for RP will be to improve vision and/or reduce the rate of vision loss; thus the sources that lead to increased variability of vision need to be identified and alleviated to enable precise evaluation of interventions and improve patients' quality of life.
Status | Completed |
Enrollment | 50 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with diagnosed retinitis pigmentosa Exclusion Criteria: - Very severe vision loss (i.e., light perception only) who may have difficulty performing the vision tests with their home computers - Unable to use a PC (Personal Computer) - Non-English speaking - Unable to communicate experiences - Out of town for more than one week during a 2 month period when taking the PC-based tests |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins WiImer Eye Insitute's Lions Vision Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Eye Institute (NEI), National Institute of Nursing Research (NINR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vision test reliability across multiple test administrations in relation to psychological and external factors | 2-3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |